Two Onc Docs
This is Sam and Karine, and we are Two Onc Docs! We both graduated from our Heme/Onc fellowships in 2021 and became board certified in both Hematology and Oncology. Our mission with Two Onc Docs is to create short board ...
Insights from recent episode analysis
On the show
- Dr. Michael Pishvaian3 eps
- Dr. Marc Carrier2 eps
- Dr. Laura Vater2 eps
Audience Interest
Podcast Focus
Publishing Consistency
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Based on 1 signal.
Built from
By chart position
- 🇮🇳India · Medicine#1320K to 104K
- 🇺🇸United States · MedicineHOME#10116K to 86K
- 🇻🇳VN · Medicine#36576 to 3.0K
- 🇵🇭PH · Medicine#45528 to 2.8K
- 🇳🇬NG · Medicine#49376 to 2.0K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
39K to 204K🎙 Weekly cadence·208 episodes·Last published 3d ago - Monthly Reach
Unique listeners across all episodes (30 days)
77K to 408K🇮🇳51%🇺🇸42%🇻🇳1%+5 more - Active Followers
Loyal subscribers who consistently listen
42K to 225K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 10/19/26 | Metastatic Breast Cancer 2026 UPDATE | This week’s episode is a 2026 update focusing on metastatic breast cancer, including the preferred treatment options by receptor (ER/PR/HER2) status + key toxicities of different treatments. | 13m 03s | ||||||
| 10/12/26 | Localized Breast Cancer 2026 UPDATE | This week’s episode will be focusing on treatment options for localized breast cancer. We will go all the important details on radiation, as well as therapies based on what the ER/PR/her2 receptor status is. | 17m 18s | ||||||
| 10/5/26 | Breast Cancer Screening, Prevention & Intro 2026 UPDATE | We are providing 2026 update for our breast cancer episodes, today we cover an introduction on breast cancer screening, prevention. | 17m 18s | ||||||
| 9/28/26 | ctDNA & MRD: Current Applications, Limitations & What’s Next | This week’s episode we are very excited to welcome back our special guest Dr. Hatim Husain, MD, a medical oncologist and physician-scientist at UC San Diego Moores Cancer Center, whose clinical and research expertise focuses on lung cancer and precision oncology. We further cover the topic of ctDNA, uses, limitations, and future directions. | 19m 12s | ||||||
| 9/21/26 | ctDNA, Liquid Biopsies, Methylation, NGS: What Does It All Mean? | This week’s episode we are very excited to welcome a special guest Dr. Hatim Husain, MD, a medical oncologist and physician-scientist at UC San Diego Moores Cancer Center, whose clinical and research expertise focuses on lung cancer and precision oncology. We cover the topic of liquid biopsies, ctDNA, NGS panels definitions & current uses. | 27m 00s | ||||||
| 9/14/26 | Metastatic Non-Small Cell Lung Cancer 2026 UPDATE | This week's episode focuses on metastatic non-small cell lung cancer - the quickly growing and changing systemic therapy landscape, including traditional chemotherapy, immunotherapy, and targeted agents. Since our last recording the number of FDA-approved targeted drugs has significantly expanded. | 13m 29s | ||||||
| 8/31/26 | non-small cell lung cancerstaging+4 | — | — | — | non-small cell lung cancerNSCLC+4 | — | 13m 49s | ||
| 8/24/26 | myelodysplastic syndromerisk factors+3 | — | Myelodysplastic Syndrome (MDS) | — | MDSmyelodysplastic syndrome+3 | — | 10m 12s | ||
| 8/17/26 | iron overloadhemochromatosis+3 | — | hemochromatosis | — | iron overloadhemochromatosis+3 | — | 22m 46s | ||
| 8/3/26 | malignancybiopsy+3 | — | How to Approach a New Malignancy 101 | — | malignancybiopsy+3 | — | 14m 13s | ||
| 7/28/26 | heme/onc fellowshiptransitioning from residency+3 | — | residency | — | heme/oncfellowship+4 | — | 17m 21s | ||
| 7/20/26 | Diffuse Large B-Cell LymphomaNHL+3 | — | — | — | DLBCLDiffuse Large B-Cell Lymphoma+5 | — | 12m 51s | ||
| 7/13/26 | wellnessoncology+3 | Dr. Laura Vater | — | — | oncologywellness+5 | — | 23m 58s | ||
| 6/29/26 | transitioning to attendingGI oncology+3 | Dr. Laura Vater | IU | — | fellow to attendingGI oncologist+3 | — | 19m 07s | ||
| 6/22/26 | oncologyclinical trials+3 | — | SARC 041CDK4/6 inhibitor+1 | advanced dedifferentiated liposarcoma (DDLPS) | ASCO 2026SARC 041+5 | — | 11m 34s | ||
| 6/15/26 | GU databladder cancer+4 | — | — | bladder cancerkidney cancer+1 | ASCO Annual MeetingGU data+4 | — | 14m 41s | ||
| 6/8/26 | ASCO PlenaryRASolute 302 trial+4 | — | daraxonrasibRASolute 302 trial+1 | metastatic pancreatic ductal adenocarcinoma | ASCO 2026RASolute 302+4 | — | 11m 26s | ||
| 5/25/26 | ASCO Annual MeetingGU sessions+3 | — | ASCO | Chicago | ASCOAnnual Meeting+5 | — | 11m 26s | ||
| 5/18/26 | Von Willebrand diseasebleeding disorders+3 | — | bleeding disorderVon Willebrand disease (VWD) | — | Von Willebrand diseaseVWD+5 | — | 13m 15s | ||
| 5/11/26 | Aplastic Anemiadiagnostic work-up+3 | — | Aplastic AnemiaPNH | — | Aplastic Anemiadiagnosis+5 | — | 11m 30s | ||
| 5/4/26 | metastatic bladder cancertreatment options+4 | — | urothelial carcinoma | — | metastatic bladder cancertreatment options+4 | — | 9m 20s | ||
| 4/27/26 | bladder cancerpathology+3 | — | localized bladder cancer | 2026 | bladder cancerlocalized cancer+5 | — | 13m 21s | ||
| 4/20/26 | anniversarypodcast future+3 | — | Two Onc DocsBladder Cancer | — | Two Onc Docshematology+3 | — | 12m 00s | ||
| 4/13/26 | pancreatic cancersupportive care+3 | Dr. Michael Pishvaian | Johns Hopkins Kimmel Cancer CenterTumor Board Tuesday | — | pancreatic cancersupportive care+3 | — | 14m 01s | ||
| 4/6/26 | metastatic pancreatic cancer1L treatments+3 | Dr. Michael Pishvaian | Johns Hopkins Kimmel Cancer CenterTumor Board Tuesday | — | metastatic pancreatic cancer1L treatments+3 | — | 25m 07s | ||
| 3/30/26 | Pancreatic Cancerrisk factors+3 | Dr. Michael Pishvaian | Johns Hopkins Kimmel Cancer CenterTumor Board Tuesday | — | localized pancreatic cancerrisk factors+3 | — | 37m 00s | ||
| 3/23/26 | ASCO GUprostate cancer+3 | — | ASCO GU | San Francisco | ASCO GUprostate cancer+5 | — | 12m 09s | ||
| 3/16/26 | Neuroendocrine Tumorsdiagnosis+3 | — | Neuroendocrine Tumorsgastro-entero-pancreatic NETs | — | Neuroendocrine TumorsNET+3 | — | 23m 35s | ||
| 3/9/26 | Venous ThromboembolismCancer+5 | Dr. Marc Carrier | — | — | VTEcancer+6 | — | 14m 24s | ||
| 3/2/26 | Venous ThromboembolismCancer+3 | Dr. Marc Carrier | University of Ottawa | — | VTEcancer+3 | — | 12m 05s | ||
| 2/24/26 | ASCO GUcancer research+4 | — | ASCOprostate cancer+3 | San Francisco | ASCO GUcancer+6 | — | 11m 35s | ||
Showing 31 of 208
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Chart history for Two Onc Docs
Peaked at #13 in India, currently #13 in India.
| Market | Genre | Peak | Current | Trend |
|---|---|---|---|---|
| India | — | #13 | #13 | — |
| VN | — | #36 | #36 | — |
| PH | — | #45 | #45 | — |
| NG | — | #49 | #49 | — |
| India | — | #52 | #52 | — |
| CO | — | #68 | #68 | — |
| New Zealand | — | #70 | #70 | — |
| SG | — | #70 | #70 | — |
| United States | — | #101 | #101 | — |
| RO | — | #107 | #107 | — |
| HK | — | #109 | #109 | — |
| CH | — | #114 | #114 | — |
| Japan | — | #137 | #137 | — |
| TR | — | #163 | #163 | — |
| IL | — | #168 | #168 | — |
| TH | — | #169 | #169 | — |
| KE | — | #176 | #176 | — |
| Mexico | — | #189 | #189 | — |
Chart Positions
18 placements across 17 markets.
Chart Positions
18 placements across 17 markets.